AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and ...

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) and Natera, Inc. today announced they have entered into a three-year agreement whereby Illumina will supply Natera with the HiSeq® 2500 ...

Large prospective study to evaluate a non-invasive prenatal screening test AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, ...

The most recent study conducted by Report Ocean, titled “Global United States Non Invasive Prenatal Testing Market Size, Share, Pricing, Trends, Growth, Report and Forecast 2023-2030,” presents a ...

An expectant mom got a $750 bill for a blood test to check for genetic abnormalities in her baby. Then she tried to figure out why it was so high. Offered a cash price for a prenatal genetic test? It ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical ...

When Mara Varona was pregnant she decided to take a common prenatal blood test to screen for genetic conditions. It was part of a proactive approach she and her husband took to pregnancy. "We're just ...